The Kaplan-Meier survival analysis of glioma patients from the TCGA (Fig. 3G) and CGGA (Fig. 3H) databases indicated that lower expression of FZD3 and β-catenin predicted better prognosis. This evidence concerns the gene FZD3 and central nervous system cancer.